Clovis Oncology, Inc. (NASDAQ:CLVS) Files An 8-K Results of Operations and Financial ConditionItem 2.02
Clovis Oncology, Inc. (NASDAQ:CLVS) Files An 8-K Results of Operations and Financial Condition
On August2, 2017, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June30, 2017.A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 2.02 of Form 8-K and the information incorporated by reference herein, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
Number and Description
| 99.1 | Press Release, dated August 2, 2017. |
Clovis Oncology, Inc. ExhibitEX-99.1 2 a51619242ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Clovis Oncology Announces Second Quarter 2017 Operating Results Strong second quarter of launch for Rubraca® (rucaparib) in U.S. with $14.6M reported in net sales Positive topline data from the ARIEL3 study reported on June 19,…To view the full exhibit click here
About Clovis Oncology, Inc. (NASDAQ:CLVS)
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).
